Keryx Biopharmaceuticals (KERX) Receives Consensus Rating of “Hold” from Brokerages

Keryx Biopharmaceuticals (NASDAQ:KERX) has earned a consensus recommendation of “Hold” from the seven brokerages that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $6.67.

Several analysts have recently weighed in on KERX shares. Morgan Stanley lowered their price objective on shares of Keryx Biopharmaceuticals from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Thursday, February 8th. ValuEngine cut shares of Keryx Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, February 22nd. BidaskClub raised shares of Keryx Biopharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, February 24th. Finally, Zacks Investment Research raised shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday.

How to Become a New Pot Stock Millionaire

Shares of Keryx Biopharmaceuticals stock traded down $0.06 on Thursday, hitting $4.77. 1,486,181 shares of the company traded hands, compared to its average volume of 1,283,073. The company has a debt-to-equity ratio of -8.87, a quick ratio of 2.49 and a current ratio of 3.12. The stock has a market cap of $521.99, a P/E ratio of -5.42 and a beta of 2.61. Keryx Biopharmaceuticals has a 12-month low of $3.92 and a 12-month high of $8.38.

Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings data on Wednesday, February 7th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by ($0.08). The company had revenue of $18.70 million for the quarter, compared to analysts’ expectations of $17.53 million. Keryx Biopharmaceuticals had a negative net margin of 269.52% and a negative return on equity of 10,954.62%. The business’s quarterly revenue was up 96.8% compared to the same quarter last year. During the same quarter last year, the business posted ($0.32) EPS. analysts predict that Keryx Biopharmaceuticals will post -0.61 earnings per share for the current year.

In related news, COO Christine A. Carberry sold 9,048 shares of the stock in a transaction on Thursday, January 18th. The shares were sold at an average price of $4.87, for a total transaction of $44,063.76. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, General Counsel Brian Adams sold 5,652 shares of the stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $4.81, for a total transaction of $27,186.12. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 41,362 shares of company stock worth $199,640. 2.58% of the stock is owned by insiders.

A number of institutional investors have recently made changes to their positions in KERX. Abrams Capital Management L.P. grew its holdings in Keryx Biopharmaceuticals by 69.9% in the 4th quarter. Abrams Capital Management L.P. now owns 9,719,176 shares of the biopharmaceutical company’s stock worth $45,194,000 after acquiring an additional 4,000,000 shares during the last quarter. Clearbridge LLC grew its holdings in Keryx Biopharmaceuticals by 67.7% in the 4th quarter. Clearbridge LLC now owns 2,692,744 shares of the biopharmaceutical company’s stock worth $12,521,000 after acquiring an additional 1,087,120 shares during the last quarter. Rice Hall James & Associates LLC grew its holdings in Keryx Biopharmaceuticals by 19.4% in the 4th quarter. Rice Hall James & Associates LLC now owns 1,911,657 shares of the biopharmaceutical company’s stock worth $8,889,000 after acquiring an additional 310,485 shares during the last quarter. Virtus Fund Advisers LLC bought a new stake in Keryx Biopharmaceuticals in the 4th quarter worth $980,000. Finally, First Trust Advisors LP bought a new stake in Keryx Biopharmaceuticals in the 4th quarter worth $749,000. 65.42% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Keryx Biopharmaceuticals (KERX) Receives Consensus Rating of “Hold” from Brokerages” was posted by Macon Daily and is owned by of Macon Daily. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://macondaily.com/2018/04/19/keryx-biopharmaceuticals-kerx-receives-consensus-rating-of-hold-from-brokerages-updated.html.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply